FDA will set the FY 2024 fee for its Voluntary Qualified Import Program at $14,975, it said in a notice. The fee, effective on Aug. 1, is up from $12,962 last year (see 2207270030) and is required from food importers and must be paid by Oct. 1 to begin participation in the VQIP trusted trader program for the period beginning Oct. 1, the agency said. The fee will remain in effect through Sept. 30, 2024, it said.
FDA set potential FY 2024 fees for import reinspections, domestic and foreign facility reinspections, and recall activities the agency performs if a firm fails to comply with a mandatory recall order, though it still isn't invoicing for services associated with the fees, it said in a notice. The agency set FY24 fees of $291 per hour for domestic services involving travel and $312 hourly if foreign travel is required.
On July 25, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 24, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 21, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 20, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
On July 11-20 the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The FDA should push back its deadline for implementation of new cosmetics facility registration requirements of the Modernization of Cosmetics Regulation Act of 2022, the National Customs Brokers & Forwarders Association of America said in a July 13 letter.
FDA will continue its policy of not requiring on-site audits for importers under the agency’s preventive controls and Foreign Supplier Verification Program regulations where COVID-19 travel advisories make them impractical until further notice, despite the recent end to the government’s public health emergency in May, the agency said in a revised guidance document released July 13.
On July 10, FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of: